ATRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Atara Biotherapeutics Inc (ATRA) is not a good buy for a beginner investor with a long-term focus and $50,000-$100,000 to invest. The company's financial performance is deteriorating, with significant revenue and income declines. Additionally, the stock faces legal challenges, negative hedge fund sentiment, and no clear positive catalysts. Technical indicators are neutral, and there are no proprietary trading signals suggesting a strong buy opportunity.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral at 63.009, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 4.943, with resistance at 5.321 and support at 4.564.
Gross margin increased by 17.96% YoY to 93.48%, indicating some operational efficiency improvements.
Multiple class action lawsuits alleging misleading statements and securities violations. Hedge funds are selling heavily, with a 192.53% increase in selling activity last quarter. Financial performance has significantly deteriorated, with revenue down 95.13% YoY and net income down 73.17% YoY.
In Q4 2025, revenue dropped by 95.13% YoY to $1,595,000. Net income fell by 73.17% YoY to -$3,406,000. EPS declined by 78.99% YoY to -$0.25. Despite these declines, gross margin improved to 93.48%, up 17.96% YoY.
No recent analyst rating or price target changes were provided.
